GlobeNewswire·Feb 24, 2026, 4:05 PM ET

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics dosed the first patient in the Phase 1b registrational trial for SER-252 in advanced Parkinson's disease on February 24, 2026.
The trial evaluates safety, tolerability, pharmacokinetics, & preliminary efficacy of SER-252 in patients with inadequate symptom control from standard-of-care therapies.
Blinded evaluation of safety & tolerability data by the Safety Monitoring Committee from Cohort 1 is expected to enable advancement to Cohort 2 in the third quarter of 2026.
The Phase 1b trial serves as the registrational study for an FDA-aligned 505(b)(2) NDA pathway.
Dosing activities are underway at global clinical sites, including Australia, where Serina has partnerships with Parkinson's Australia & Neuroscience Trials Australia for patient enrollment.
SER-252 is an investigational apomorphine therapy developed using Serina's proprietary POZ Platform™ to provide continuous dopaminergic stimulation (CDS).
Preclinical studies suggest SER-252 may provide CDS without the skin reactions often associated with current apomorphine therapies.
Serina is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, leveraging its POZ technology to optimize small molecules, RNA-based therapeutics, & antibody-based drug conjugates.